Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tenecteplase in Central Retinal Artery Occlusion
NCT04526951Phase 3Completed
- Sponsor
- Oslo University Hospital
- Start
- Oct 2020
- Primary completion
- Jun 2025
- Modality
- rProtein (Recombinant Protein), Biologic
- Countries
- 6
01
Overview
Phase 3, randomised, double-blind trial of tenecteplase in central retinal artery occlusion (CRAO) (2 arms), sponsored by Oslo University Hospital. Primary endpoint: Proportion of patients with <= 0.7 logMAR visual acuity in the affected eye at 30 days. Started Oct 2020; status: completed.
02
Drugs
tenecteplase
03
Conditions
central retinal artery occlusion (CRAO)
Beyond the preview
Go deeper on NCT04526951.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04526951.